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Objectives: To evaluate the effect of subject-controlled, on-demand, dorsal genital nerve
(DGN) stimulation on non-neurogenic urgency urinary incontinence (UUI) in a domestic
setting.
Materials and Methods: Non-neurogenic patients >18 years with overactive bladder
symptoms and UUI were included. Exclusion criteria were mainly stress urinary
incontinence. Patients underwent 1 week of subject-controlled, on-demand, DGN
stimulation, delivered by a percutaneously placed electrode near the DGN connected
to an external stimulator (pulse-rate 20Hz, pulse-width 300µs). Patients activated the
stimulator when feeling the urge to void and stimulated for 30 s. The amplitude was
set at the highest tolerable level. A bladder diary including a severity score of the UUI
episodes/void (scores: 0 = none, 1 = drops, 2 = dashes, 3 = soaks) and a padtest was
kept 3 days prior to, during, and 3 days after the test period. The subjective improvement
was also scored.
Results: Seven patients (4 males/3 females) were enrolled, the mean age was 55 years
(range 23–73). Six completed the test week. In the remaining patient the electrode
migrated and was removed. 5/6 finalized the complete bladder diary, 1/6 recorded
only the heavy incontinence episodes (score = 3). 4/6 completed the padtest. In all
patients who finalized the bladder diary the number of UUI episodes decreased, in 3/5
with ≥60%. The heavy incontinence episodes (score = 3) were resolved in 2/6 patients,
and improved ≥80% in the other 4. The severity score of the UUI episodes/void was
improved with ≥ 60% in 3/5 patients. The mean subjective improvement was 73%.
Conclusion: This feasibility study indicates that subject-controlled, on-demand DGN
stimulation using a percutaneously placed electrode is possible over a longer time period,
in a home setting, with a positive effect on non-neurogenic overactive bladder symptoms
with UUI. Although the placement is an easy procedure, it is difficult to fixate the electrode
to keep it in the correct position. Improvements in hardware, like a better fixated electrode
and an easy to control stimulator, are necessary to make SODGNS a treatment possibility
in the future.
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INTRODUCTION
In patients with urgency urinary incontinence (UUI) the time
between the sensation to void and reaching the toilet is mostly
too short to prevent incontinence. UUI is often challenging to
treat and affects the quality of life of many people negatively.
Conservative treatment comprises bladder and behavioral
training with or without anticholinergics or mirabegron. Side
effects, like dry mouth and constipation, strongly decrease
compliance of patients to treatment, are an important reason
to discontinue treatment (Veenboer and Bosch, 2014). More
invasive treatments can be considered in patients who do
not tolerate side effects or who do not respond satisfactorily.
Intravesical injections of Botulinum toxin and neuromodulation
are examples of more invasive or surgical treatment. Drawbacks
of intravesical injections of Botulinum toxin are the temporary
effect which demands repeated injections and the risk for residual
urine or urinary retention with the need for self-catheterisation.
With regard to neuromodulation are Percutaneous Tibial
Nerve Stimulation (PTNS) and Sacral Nerve Stimulation (SNS)
nowadays widely adopted as a treatment which diminishes UUI
(van Kerrebroeck et al., 2007; Peters et al., 2010, 2013; Groen
et al., 2011). With PTNS a moderate or markedly result is seen in
55% of the patients (Peters et al., 2010), however PTNS is a rather
time consuming therapy. Patients need to visit the office once a
week for 12 weeks. A electrode needle has to be inserted correctly
for each stimulation session. To maintain the treatment effect
patients need to continue their visits more than once a month
(Peters et al., 2013). With SNS therapy the success rate, ≥50%
improvement, is around 62–68% (van Kerrebroeck et al., 2007;
Groen et al., 2011). Complete continence is reached in only 15%
of the patients (Groen et al., 2011).
Dorsal genital nerve (DGN) stimulation has been used in
research settings and seems to be promising for future use
in clinical care (Goldman et al., 2008; Martens et al., 2011a;
Farag et al., 2012). The DGN, being the dorsal penile nerve
(DPN) or clitoral nerve (DCN), is a terminal branch of
the pudendal nerve. Previous studies have shown that DGN
stimulation can inhibit involuntary bladder contraction in an
acute investigational setting (Lee et al., 2005; Martens et al.,
2011b). When inhibition of the detrusor contraction can be
effectuated with on demand DGN stimulation in a domestic
setting, complete continence could theoretically be achieved.
Using on demand stimulation to inhibit an involuntary detrusor
contraction the patient gains time to reach the toilet. A
study on subject-controlled, on-demand, dorsal genital nerve
stimulation (SODGNS) through self-adhesive surface electrodes
in neurogenic patients with detrusor overactivity who had intact
bladder sensations showed a reduction in their UUI episodes
during 5 days of stimulation at home (Opisso et al., 2013).
Another study used a percutaneous electrode for continuous
stimulation at home in non-neurogenic women with UUI, who
also reported a reduction in UUI episodes (Goldman et al., 2008).
The results of subject-controlled on-demand stimulation with
an implanted electrode in non-neurogenic patients with UUI in
daily life are not known yet. Previous studies used continuous
stimulation instead of on-demand stimulation, included patients
with neurogenic detrusor overactivity instead of non-neurogenic
UUI, or only acute effects of on-demand stimulation in a
laboratory setting were used instead of application in a out of
hospital setting with daily activities (Martens et al., 2011b; Opisso
et al., 2013).
The purpose of the current study was to investigate the effect
of SODGNS on overactive bladder (OAB) with UUI in a home
testing period using an implanted electrode in non-neurogenic
patients with refractory OAB and UUI.
MATERIALS AND METHODS
The study was approved by the accreditedmedical research ethics
committee, Committee on Research Involving Human Subjects
region Arnhem-Nijmegen (The Netherlands) and conducted
according to the principles expressed in the declaration of
Helsinki. Written informed consent was obtained. The inclusion
criteria were: age >18 years old, OAB with UUI, and more than
4 UUI episodes a day, patients who are willing and aiming to
follow all requirements of the protocol. The exclusion criteria:
Neurogenic OAB, pure stress urinary incontinence, neurological
disease, skin lesions at the implantation site, an increased risk
of infections, poor wound healing, bleeding tendency, DGN
or pudendal nerve or sacral root lesions, a cardiac pacemaker,
peripheral neuropathy, and pregnancy.
Patients on anticholinergics had a wash-out period of 2 weeks.
All patients kept a bladder diary, a pad test and scored once daily
the Patient Perception of Intensity of Urgency Scale (PPIUS), 3
days prior to and during the 7 days home stimulation days. The
bladder diary contained frequency, micturition volume, intake,
and the severity of UUI estimated by the Severity Score of
Incontinence Episodes (SSIE) (0 = none, 1 = drops, 2 = dashes,
3 = soaks). At the end of the SODGNS week, the subjective
improvement was scored. All subjects underwent a test period
of SODGNS for 4 h using self-adhesive skin electrodes. In males
we used 25mm-diameter round PALS electrodes, (Axelgaard
manufacturing Co., Fallbrook, CA,). The cathode and anode were
placed, proximally and distally, respectively, on the dorsum of the
penile shaft. In females a PALS electrode was positioned next to
the clitoris as anode and a Neuroline700 (Ambu, A/S, Ballerup,
Denmark) as cathode on the clitoris (Figure 1).
The electrodes were connected to a handheld battery powered
current controlled stimulator (Odstock O2CHS, Salisbury,
Wiltshire, UK). Stimulation was initiated by pushing a button
and lasted for 30 s. They started stimulation every time as soon
as they felt the need to go to the toilet to pass urine. However,
when they were at the toilet and wanted to void, they did not
activate the stimulator and voiding could proceed as normal.
The stimulator was set to square pulses at a pulse-rate of 20Hz
and a pulse-width of 300µs. The stimulation amplitude was
set at the highest tolerable level. If during the test period with
surface electrode stimulation the UUI decreased subjectively they
underwent percutaneous placement of an electrode (Medtronic
InterStimModel 3057 Test Stimulation Lead, Minneapolis, USA)
under local anesthesia (lidocaine 1%). The electrode placement
was performed in the outpatient clinic. Firstly, a needle electrode
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FIGURE 1 | Stimulation setup self-adhesive skin electrodes. (A) Stimulation setup. (B) Stimulation sites. From Opisso et al. (2013), with permissions.
FIGURE 2 | Stimulation setup percutaneous lead electrode insertion. (A) Female. (B) Male. A hollow needle electrode is used to find the correct position and
insert the lead electrode.
was inserted in the pubic area in the direction of the clitoris or
the penile base. Test stimulation was applied and patients were
asked where the stimulation was felt. If the patient reported a
sensation localized at the clitoris or at the glans penis, it was
concluded that proper placement was obtained (Figure 2). After
proper needle positioning the lead was introduced, fixated to the
skin, and connected to an external voltage controlled stimulator
(Medtronic inc., Model 3625, Minneapolis, USA). The stimulator
was set to square pulses at a pulse-rate of 20Hz and a pulse-width
of 300µs. This stimulator was activated by turning the amplitude
control button to its maximum and was turned off by turning
the control button back to 0. The maximum was limited to the
patient’s highest tolerable level. The patients were sent home for
1 week. Conform the instructions for the test period patients were
asked to stimulate every time as soon as they felt the need to
go to the toilet to pass urine for 30 s. Improvement was defined
as ≥60% reduction in UUI episodes.
RESULTS
Seven patients, 4 males and 3 females were enrolled. The
mean age was 55 years old (range 24–73). All patients had a
positive result on their UUI during the test-stimulation with
skin electrodes and subsequently an electrode was implanted.
The implantation took 10–40min. In four patients the electrode
dislocated after stepping off the treatment bench where after
upon stimulation the sensation in the desired location was gone.
In those patients a new electrode was placed.
At the time of lead placement, the stimulus amplitude at which
the subject first felt the stimulus (sensation threshold) was 1.6 ±
0.8V (range 1–3V), and the maximum tolerable amplitude was
7.6 ± 2.2V (range 6–10V). Six out of seven patients completed
the protocol. One patient did not feel the sensation in the proper
position after 2 days of home stimulation, likely due to migration
of the electrode, and the electrode was removed. At the end of
the week of stimulation the sensation threshold amplitude was
higher but not clinical significantly (1.8± 0.4V, range 1–2V).
Three out of six patients reported that the location of sensation
had slightly changed during the week of home stimulation,
where after the subjective effect of stimulation on their UUI was
slightly less.
Of the six patients who completed the week of home
stimulation, 4/6 completed the padtest, all completed the PPIUS,
5/6 finalized the complete bladder diary and the remaining one
recorded only the heavy IE (3 = soaks) and the nighttime
frequency in her bladder dairy.
Frontiers in Neuroscience | www.frontiersin.org 3 February 2016 | Volume 10 | Article 24
van Breda et al. DGN Stimulation to Treat Incontinence
TABLE 1 | Mean of variables of the days prior to stimulation and the days during of SODGNS.
Patient 1 2 3 4 5 6
Gender M M F F M F
Mean number of IE/day Before SODGNS 14.0 6.0 – 8.3 17.7 8.0
SODGNS 13.5 0.7 – 3.3 14.8 0.5
Improvement (%) 4 88 – 60 16 94
Mean heavy leaks/day Before SODGNS 1.0 1.0 3.3 2.7 5.0 2.3
SODGNS 0.2 0.0 0.3 0.5 1.0 0.0
Improvement (%) 80 100 91 81 80 100
Mean SSIE/void Before SODGNS 2.0 0.6 – 1.9 2.2 2.2
SODGNS 1.6 0.1 – 0.5 1.3 0.1
Improvement (%) 20 83 – 74 41 95
Mean padtest (g/day) Before SODGNS 63.0 – 402.7 76.0 – 313
SODGNS 16.7 – 295.2 55.8 – 3.3
Improvement (%) 73 – 27 27 – 99
Mean daytime frequency Before SODGNS 14.0 10.7 – 8.3 15.7 7.0
SODGNS 14.0 8.0 – 8.0 13.8 5.0
Improvement (%) 0 25 – 4 12 29
Mean nighttime frequency Before SODGNS 0.3 3.3 2.7 1.0 2.0 1.0
SODGNS 0.0 2.2 1.5 1.0 1.3 0.2
Improvement (%) 100 33 44 0 35 80
Mean PPIUS Before SODGNS 3.0 3.5 4.0 3.8 3.2 4.0
SODGNS 2.0 1.3 2.5 2.1 3.3 2.5
Improvement (%) 33 67 38 45 −3 38
Subjective improvement (%) 90 70 70 80 30 100
SODGNS, subject-controlled, on demand dorsal genital nerve stimulation; SSIE, severity score of incontinence episodes; PPIUS, patient perception of intensity of urgency scale.
Results are shown in Table 1, and the results per patient per
day are shown in Table 2.
The heavy IE (3 = soaks) resolved completely in 2/6 patients,
and 4/6 patients had a≥80% improvement of the heavy leaks (91,
81, 80, and 80%).
In all of the five patients who finalized the complete bladder
diary the number of UUI episodes decreased. In 3/5 it improved
with≥60% (94, 88, 60%) the other two improved with 16 and 4%.
The SSIE/void was improved with at least 60% in 3/5 patients
(95, 83, 74%) the other 2/5 patients had an improvement of 41
and 20%.
In 4/5 patients the daytime frequency decreased. The mean
number of voids per day with and without SODGNS were 10
(range 5–14) and 11 (range 7–16), respectively. The nighttime
frequency decreased in 5/6 patients, and was unchanged in the
remaining one.
The voided volume per day during the test week was
comparable to the days before the test week, 1809 (±346)
ml/day respectively 1821 (±553) ml/day. The mean voided
volume (MVV) increased in 4/5 patients. The MVV
with SODGNS was 223 (±148) ml and without SODGNS
184 (±93) ml.
The PPIUS improved in 5/6 patients. All patients used
pads for their incontinence, four completed the padtest. Of
the four subjects who completed the padtest, 2 had at least
60% improvement (99 and 73%) the other 2 had both 27%
improvement. The subjective improvement reported by the
patients were: 100, 90, 80, 70, 70, and 30%.
Patientsmentioned that the SODGNS had a better effect, when
the stimulator was activated without delay in response to the
urge to void. They also mentioned that with the button they
had to turn activating the stimulator which was used during the
test week, was more inconvenient compared to the pushbutton,
which was used during the 4 h test period with the skin
electrodes.
After the stimulation week, one patient reported that the effect
on the UUI was immediately gone and 5/6 patients reported that
the effect waned over time. They reported to have a decreasing
effect over a time period from 1–7 days.
During the week of home stimulation 1 patient experienced a
mild muscle pain in her pelvic floor. One patient experienced a
headache at the first day and one patient had 1 day of chest pain,
cardiac evaluation showed no abnormalities. At explantation of
the electrode 4/6 patients had a temporary small hematoma
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TABLE 2 | Mean SSIE/void per day and mean Pad test per day.
Patient 1 2 3 4 5 6
Gender M M F F M F
SSIE/void Before SODGNS 1 2.1 0.9 – 1.4 2.2 2.3
2 1.9 0.5 – 2.1 2.1 2.4
3 2.1 0.4 – 2.1 2.3 2.0
SODGNS day 1 1.3 0.0 – 1.0 1.3 0.0
2 1.7 0.0 – 0.3 1.2 0.0
3 1.6 0.1 – 0.6 1.5 0.0
4 1.7 0.2 – 0.4 1.3 0.2
5 1.6 0.1 – 0.3 1.2 0.3
6 1.7 0.1 – 0.6 1.2 0.2
Pad test (g/day) Before SODGNS 1 59 – 450 114 – 315
2 59 – 450 38 – 315
3 57 – 338 – – 324
SODGNS 1 13 – – 160 – 0
2 32 – 336 6 – 0
3 15 – 364 64 – 0
4 15 – 200 70 – 8
5 11 – 334 12 – 5
6 14 – 242 23 – 7
SODGNS, subject-controlled, on demand dorsal genital nerve stimulation; SSIE, severity score of incontinence episodes.
and in one patient some redness at the implantation site was
observed. All resolved spontaneously.
DISCUSSION
This pilot study demonstrates a decrease in UUI with subject
controlled, on demand DGN stimulation using a percutaneously
placed electrode in patients with idiopathic refractory UUI in a
home setting. One patient was almost 100% dry, she described
that she was completely dry except for the moments when she
wasn’t able to activate the stimulator immediately when she
felt the urge to void, e.g., because she was driving her car or
first had to undo her coat to reach the stimulator. The other
patients also mentioned that the SODGNS had a better effect,
when the stimulator was activated without delay in response
to the urge to void. This was difficult to achieve in every
episode since the stimulator was in most of the time in their
pocket, which always gave a little delay. Patients also mentioned
that the button they had to turn on for activation of the
stimulator was more inconvenient compared to the pushbutton,
and therefore more time consuming and causing delay. Probably,
better results would have been achieved with a quicker and
easier activation of the stimulator. This implies that immediate
stimulation when feeling urge is important. This is in line with
Opisso’s report in 2008 (Opisso et al., 2008). He described that
in patients with neurogenic detrusor overactivity, the sooner the
onset of DGN stimulation during a detrusor contraction, the
greater the likelihood of stopping the contraction and therefore
preventing incontinence. Ideally, instead of manually turning or
pushing a button while feeling urge, a sensor that continuously
monitors bladder activity should be used to set off the conditional
stimulation. In this way a closed loop system could be formed.
There is ongoing research into bladder sensors, but until now no
suitable device is available for clinical application (Melgaard and
Rijkhoff, 2014).
Besides the decrease in UUI, the daytime and nighttime
frequency also decreased with SODGNS. The mean volume/void
increased. This supports the assumption that patients can
suppress the urge to void with SODGNS, and gain time before
they have to go to the toilet, and gain time to reach the toilet
without UUI.
Another advantage of conditional compared to continuous
stimulation is that the stimulation is only felt when activating
the stimulator during the sensation of urge instead of feeling
the stimulation continuously. The sensation of the stimulation
was experienced as less annoying by the patients than the
sensation of urgency. During an urgency episode the stimulation
amplitude was experienced less intense, therefore the amplitude
of SODGNS can be set to a higher amplitude compared to
continues stimulation. With a higher stimulation amplitude a
better effect on the bladder inhibition could be achieved and
therefore a higher continence rate can be expected. Another
further advantage is that SODGNS reduces power consumption
compared to continuous stimulation due to reduction in
stimulation time.
This study is performed in non-neurogenic OAB patients.
Previous DGN stimulation in a domestic setting has been
described in neurogenic OAB patients with comparable results
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(Wheeler et al., 1994; Lee and Creasey, 2002; Opisso et al.,
2013). Opisso performed SODGNS, through self-adhesive skin
electrodes, in patients with intact bladder sensation and
described a decrease in their UUI (Opisso et al., 2013). Lee et al.
(Lee and Creasey, 2002) published a case report of SODGNS
with skin electrodes in a 33 year old spinal cord injured (SCI)
male. SODGNS diminished his UUI episodes. Continuous DGN
stimulation is described by Wheeler et al. (1994) in this study
2 males with SCI and UI due to detrusor overactivity fulfilled 2
weeks of continues DGN stimulation through surface electrodes
and became continent.
Comparing this study with SODGNS to the publication
of Goldman et al. (2008) who performed continuous DGN
stimulation in non-neurogenic patients a stronger effect on UUI
was found with SODGNS in our patients, although both studies
contained only a small number of patients and results must be
interpreted carefully. With continuous DGN stimulation 79%
of the patients experienced a reduction in UUI episodes of
whom 47% experienced a≥50% reduction in UUI episodes.With
SODGNS all patients experienced a reduction in incontinences
episodes and a ≥50% reduction was seen in 60% of the patients.
The number of heavy leaks decreased with ≥50% in 85% of
the patients with continuous DGN stimulation, with SODGNS
this was seen in all patients. Eighty-eight percent of the patients
experienced a reduction in pad weight with continues DGN
stimulation. Of them 76% experienced at least 50% reduction.
With SODGNS all patients who completed the padtest had a
reduced pad weight and half of them (2/4) with at least 50%.
Although this is a pilot study with a small number of patients
SODGNSmight have better results as compared with continuous
DGN stimulation.
In this study we used self-adhesive skin electrodes for the test
period. All patients who were included for this study responded
during this test period. Lee et al. (2005) showed that there is
no difference between conditional DGN stimulating with surface
electrodes comparing to percutaneous placed electrodes. So if
SODGNS would be possible with an definitive implant, the
screening period before implanting, the PNE or 1st stage tined
lead for SNS, can be done with less invasive surface electrodes.
All subjects tolerated the DGN stimulation well. Patient’s
commends were about the usability of the technique, especially of
the activation system as mentioned above. Theoretically, damage
to the nerve or infection by the percutaneous electrode could
occur. Only minor adverse events were noticed during short-
term follow-up. Up to now no long-term results of electrodes
near the DGN are available because of only acute settings or
short-term follow-up in SODGNS studies, besides studies and
experiences with PTNS and SNS. The setting of the current
study would intervene with sexual intercourse and a complete
implant with an electrode that doesn’t migrate would therefore
be desirable. In previous studies DGN stimulation did not evoke
sexual feelings or responses (Goldman et al., 2008; Martens et al.,
2011a). As patients use the stimulation only on demand, the
stimulation does not interfere with intercourse as long as the
stimulation is not activated by the patient, which is less likely to
be needed during sexual intercourse due to sexual stimulation
of the DGN. The influence of long-term DGN stimulation on
sexuality is not known. Continuous DGN stimulation might
theoretically desensitize sexual responses. With SODGNS this
risk of desensitizing might probably be lower, due to less and
intermittent stimulation.
One patient could not complete the week of home stimulation
due to dislocation of the lead. Of the six patients who completed
the week of SODGNS, three reported that the sensation had
slightly changed from position during the week of home
stimulation where after the effect subjectively deteriorated
slightly. This shows that this percutaneously placed lead is not
very prone to stay in the initial location. For future treatment
an electrode with a more stable position is necessary. An
percutaneous lead connected to an external stimulator is not ideal
nor patient friendly. Further development requires at least a fully
implanted system consisting of an electrode and a pacemaker,
which can be activated by a wireless activator that is easy to use.
CONCLUSION
This feasibility study indicates that it is possible to administer
SODGNS using a percutaneously placed electrode, over a longer
time period, in a home setting, with a positive effect on OAB
with UUI. The electrode can be placed in an outpatient setting
by a minimal invasive pre-pubic approach and is well tolerated
by the patients. Although the placement is an easy procedure it is
difficult to fixate the electrode to keep it in the correct position.
Improvements in hardware, like a better fixated electrode and
an easy to control stimulator, are necessary to make SODGNS
a treatment possibility in the future.
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